There's never any guarantees in the investment world, and it's always unnerving to experience a drop. Thankfully I'm still well into the green. And sometimes in need of being reminded that nothing but nothing goes up in a straight line.
ZIOP went up too far too fast and a correction was certainly due. The hype about a biotech bubble certainly magnified the situation. However, I look back at the orginal reaction to the MD Anderson announcement, and then consider current events. I personally suspect that there is some serious buying going on even now. No doubt they are being stealthful and attempting to load up without creating any price pressure. This back-to-back news the past two days is too significant for knowledgeable investors to ignore.
A lot has been added to the arsenal, and I seriously doubt Kirk is done yet. Just the fact that he's played down the last two developments on the ZIOP side tells me there's another piece coming. Not to mention the fact that the very fact that it's been played down is completely contrary to the short "pump and dump" thesis. It that was the plan, they'd be shrieking from the rooftops the past two days, as opposed to the low key PR approach they've taken.
Everything Kirk had done is following the path he's laid out. Those who have followed what he openly stated, knows what still lies ahead. What I'm really looking forward to is the next CC, even if I have to wait for the Q1 release. I suspect the number of trials going forward has increased as the direct result of these past two collaborations . . .
All the above is obviously my opinion, however, I'm confident in the due diligence I've put in. Now, if someone will just buy some May $20 calls for the same outrageous prices they paid me the past couple months :D
Trust all's well with you ;)
ZIOP went up too far too fast and a correction was certainly due. The hype about a biotech bubble certainly magnified the situation. However, I look back at the orginal reaction to the MD Anderson announcement, and then consider current events. I personally suspect that there is some serious buying going on even now. No doubt they are being stealthful and attempting to load up without creating any price pressure. This back-to-back news the past two days is too significant for knowledgeable investors to ignore.
A lot has been added to the arsenal, and I seriously doubt Kirk is done yet. Just the fact that he's played down the last two developments on the ZIOP side tells me there's another piece coming. Not to mention the fact that the very fact that it's been played down is completely contrary to the short "pump and dump" thesis. It that was the plan, they'd be shrieking from the rooftops the past two days, as opposed to the low key PR approach they've taken.
Everything Kirk had done is following the path he's laid out. Those who have followed what he openly stated, knows what still lies ahead. What I'm really looking forward to is the next CC, even if I have to wait for the Q1 release. I suspect the number of trials going forward has increased as the direct result of these past two collaborations . . .
All the above is obviously my opinion, however, I'm confident in the due diligence I've put in. Now, if someone will just buy some May $20 calls for the same outrageous prices they paid me the past couple months :D
Trust all's well with you ;)
Recent TCRT News
- Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies • GlobeNewswire Inc. • 05/26/2026 03:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 03:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 12:00:43 PM
- Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models • GlobeNewswire Inc. • 05/18/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 09:29:30 PM
- Valion Bio Appoints Melinda Lackey as General Counsel • PR Newswire (US) • 05/04/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:30:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:18:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:15:27 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 09:14:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:32:59 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 08:33:22 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 03/05/2026 04:33:21 PM
- Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders • GlobeNewswire Inc. • 03/02/2026 11:30:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 11:29:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/15/2026 09:15:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/15/2026 09:15:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/15/2026 09:15:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 01:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 10:18:31 PM
- Form 424B8 - Prospectus filed pursuant to Rule 424(b)(8) • Edgar (US Regulatory) • 12/11/2025 10:17:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2025 02:32:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2025 02:26:18 AM
